树突状细胞的功能超越抗原呈递

IF 44.5 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-08-14 DOI:10.1016/j.ccell.2025.07.003

Eynav Klechevsky

引用次数: 0

摘要

在这一期的Cancer Cell中，Chen等人发现表达dnase1l3的树突状细胞（dc）是抗肿瘤免疫的增强剂。通过降解中性粒细胞胞外陷阱，这些dc促进CD8 + T细胞浸润到肿瘤中，增强检查点阻断效果，将DNASE1L3已知的免疫调节作用扩展到肿瘤微环境的物理重塑中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dendritic cells function beyond antigen presentation

In this issue of Cancer Cell, Chen et al. identify DNASE1L3-expressing dendritic cells (DCs) as enhancers of anti-tumor immunity. By degrading neutrophil extracellular traps, these DCs promote CD8⁺ T cell infiltration into tumors and enhance checkpoint blockade efficacy, extending DNASE1L3’s known immune regulatory role to physical remodeling of the tumor microenvironment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.